News

Globus Medical Announces Leadership Transitions and Preliminary Second Quarter 2025 Sales Results

AUDUBON, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced…

6 months ago

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on…

6 months ago

Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference – The Sildenafil Cream That Raises the Bar

A first-of-its-kind solution for women’s arousal - the same active ingredient as in Viagra® for men - in a proprietary…

6 months ago

Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025

WATERTOWN, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,…

6 months ago

ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE,…

6 months ago

NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases

Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in…

6 months ago

Expanding Analyst Interest in ORYZON

New U.S. investment bank joins, bringing total coverage to ten analystsMADRID and CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) --…

6 months ago

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease

FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s DiseaseCAMBRIDGE, Mass., July 21,…

6 months ago

Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025

Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a…

6 months ago